Meeting
2014 ASCO Annual Meeting
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).
Authors
Scott Joseph Antonia
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Scott Joseph Antonia , Julie R. Brahmer , Scott N. Gettinger , Laura Quan Man Chow , Rosalyn A. Juergens , Frances A. Shepherd , Scott Andrew Laurie , David E. Gerber , Jonathan Wade Goldman , Yun Shen , Christopher Harbison , Suresh Alaparthy , Allen C. Chen , Hossein Borghaei , Naiyer A. Rizvi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01454102
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8113)
DOI
10.1200/jco.2014.32.15_suppl.8113
Abstract #
8113
Poster Bd #
294
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
First Author: Nathaniel R. Evans
Poster
2014 ASCO Annual Meeting
A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC).
First Author: David Paul Carbone
Poster
2021 ASCO Annual Meeting
Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).
First Author: John M. Varlotto
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase I study evaluating COM701 monotherapy and in combination with nivolumab in patients with advanced solid malignancies.
First Author: Ryan J. Sullivan